How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
21
IOVA Quote, Financials, Valuation and Earnings
Last price:
$2.63
Seasonality move
:
144.47%
Day range:
$2.53 - $2.68
52-week range:
$1.64 - $6.16
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.38x
P/B ratio:
1.44x
Volume:
9.1M
Avg. volume:
13M
1-year change:
-58.94%
Market cap:
$1B
Revenue:
$164.1M
EPS (TTM):
-$1.20
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IOVA
Iovance Biotherapeutics, Inc.
|
$82.2M | -$0.17 | 11.5% | -57.01% | $8.35 |
|
CATX
Perspective Therapeutics, Inc.
|
$231.1K | -$0.35 | -57.02% | -40.33% | $12.4167 |
|
ELMD
Electromed, Inc.
|
$18M | -- | 11.04% | -- | $36.00 |
|
INFU
InfuSystem Holdings, Inc.
|
$36.7M | $0.05 | -0.47% | 39.86% | $14.20 |
|
LNTH
Lantheus Holdings, Inc.
|
$368M | $1.16 | -6.5% | 18.66% | $83.85 |
|
NTLA
Intellia Therapeutics, Inc.
|
$12.2M | -$0.96 | -37.7% | -10.49% | $23.86 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IOVA
Iovance Biotherapeutics, Inc.
|
$2.55 | $8.35 | $1B | -- | $0.00 | 0% | 3.38x |
|
CATX
Perspective Therapeutics, Inc.
|
$3.7900 | $12.4167 | $281.7M | -- | $0.00 | 0% | 256.98x |
|
ELMD
Electromed, Inc.
|
$29.87 | $36.00 | $249.1M | 32.14x | $0.00 | 0% | 3.98x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.26 | $14.20 | $168M | 31.59x | $0.00 | 0% | 1.24x |
|
LNTH
Lantheus Holdings, Inc.
|
$66.92 | $83.85 | $4.4B | 28.11x | $0.00 | 0% | 3.06x |
|
NTLA
Intellia Therapeutics, Inc.
|
$13.15 | $23.86 | $1.5B | -- | $0.00 | 0% | 23.96x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IOVA
Iovance Biotherapeutics, Inc.
|
6.96% | -0.707 | 6.28% | 2.92x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 2.996 | 1.3% | 8.47x |
|
ELMD
Electromed, Inc.
|
-- | 0.920 | -- | 4.58x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.209 | 11.73% | 1.35x |
|
LNTH
Lantheus Holdings, Inc.
|
35.63% | -1.846 | 18.22% | 2.30x |
|
NTLA
Intellia Therapeutics, Inc.
|
11.58% | 3.116 | 4.9% | 5.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IOVA
Iovance Biotherapeutics, Inc.
|
$20M | -$89.8M | -50.35% | -54.43% | -133.06% | -$89.5M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
ELMD
Electromed, Inc.
|
$13.2M | $2.7M | 18.88% | 18.89% | 15.81% | -$98K |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
LNTH
Lantheus Holdings, Inc.
|
$222.4M | $43.6M | 9.52% | 14.66% | 11.36% | $94.7M |
|
NTLA
Intellia Therapeutics, Inc.
|
$8.8M | -$111.5M | -47.33% | -54.66% | -808.86% | -$76.9M |
Iovance Biotherapeutics, Inc. vs. Competitors
-
Which has Higher Returns IOVA or CATX?
Perspective Therapeutics, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of -12425.36%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About IOVA or CATX?
Iovance Biotherapeutics, Inc. has a consensus price target of $8.35, signalling upside risk potential of 227.45%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.4167 which suggests that it could grow by 223.22%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Perspective Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IOVAIovance Biotherapeutics, Inc.6 4 1 CATXPerspective Therapeutics, Inc.11 1 0 -
Is IOVA or CATX More Risky?
Iovance Biotherapeutics, Inc. has a beta of 0.765, which suggesting that the stock is 23.531% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.747, suggesting its more volatile than the S&P 500 by 74.695%.
-
Which is a Better Dividend Stock IOVA or CATX?
Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOVA or CATX?
Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.38x versus 256.98x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOVAIovance Biotherapeutics, Inc.3.38x -- $67.5M -$91.3M CATXPerspective Therapeutics, Inc.256.98x -- $209K -$26M
-
Which has Higher Returns IOVA or ELMD?
Electromed, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of 12.65%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Electromed, Inc.'s return on equity of 18.89%.
Company Gross Margin Earnings Per Share Invested Capital IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M ELMDElectromed, Inc.78.15% $0.25 $44.7M -
What do Analysts Say About IOVA or ELMD?
Iovance Biotherapeutics, Inc. has a consensus price target of $8.35, signalling upside risk potential of 227.45%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 20.52%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Electromed, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Electromed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IOVAIovance Biotherapeutics, Inc.6 4 1 ELMDElectromed, Inc.4 0 0 -
Is IOVA or ELMD More Risky?
Iovance Biotherapeutics, Inc. has a beta of 0.765, which suggesting that the stock is 23.531% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.264, suggesting its less volatile than the S&P 500 by 73.581%.
-
Which is a Better Dividend Stock IOVA or ELMD?
Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOVA or ELMD?
Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are larger than Electromed, Inc. quarterly revenues of $16.9M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 32.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.38x versus 3.98x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOVAIovance Biotherapeutics, Inc.3.38x -- $67.5M -$91.3M ELMDElectromed, Inc.3.98x 32.14x $16.9M $2.1M
-
Which has Higher Returns IOVA or INFU?
InfuSystem Holdings, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of 6.19%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About IOVA or INFU?
Iovance Biotherapeutics, Inc. has a consensus price target of $8.35, signalling upside risk potential of 227.45%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 71.91%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IOVAIovance Biotherapeutics, Inc.6 4 1 INFUInfuSystem Holdings, Inc.5 0 0 -
Is IOVA or INFU More Risky?
Iovance Biotherapeutics, Inc. has a beta of 0.765, which suggesting that the stock is 23.531% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.674, suggesting its more volatile than the S&P 500 by 67.352%.
-
Which is a Better Dividend Stock IOVA or INFU?
Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOVA or INFU?
Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are larger than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 31.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.38x versus 1.24x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOVAIovance Biotherapeutics, Inc.3.38x -- $67.5M -$91.3M INFUInfuSystem Holdings, Inc.1.24x 31.59x $36.5M $2.3M
-
Which has Higher Returns IOVA or LNTH?
Lantheus Holdings, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of 7.23%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Lantheus Holdings, Inc.'s return on equity of 14.66%.
Company Gross Margin Earnings Per Share Invested Capital IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M LNTHLantheus Holdings, Inc.57.91% $0.41 $1.7B -
What do Analysts Say About IOVA or LNTH?
Iovance Biotherapeutics, Inc. has a consensus price target of $8.35, signalling upside risk potential of 227.45%. On the other hand Lantheus Holdings, Inc. has an analysts' consensus of $83.85 which suggests that it could grow by 25.29%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Lantheus Holdings, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Lantheus Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IOVAIovance Biotherapeutics, Inc.6 4 1 LNTHLantheus Holdings, Inc.9 2 0 -
Is IOVA or LNTH More Risky?
Iovance Biotherapeutics, Inc. has a beta of 0.765, which suggesting that the stock is 23.531% less volatile than S&P 500. In comparison Lantheus Holdings, Inc. has a beta of -0.076, suggesting its less volatile than the S&P 500 by 107.602%.
-
Which is a Better Dividend Stock IOVA or LNTH?
Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lantheus Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Lantheus Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOVA or LNTH?
Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are smaller than Lantheus Holdings, Inc. quarterly revenues of $384M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is lower than Lantheus Holdings, Inc.'s net income of $27.8M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Lantheus Holdings, Inc.'s PE ratio is 28.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.38x versus 3.06x for Lantheus Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOVAIovance Biotherapeutics, Inc.3.38x -- $67.5M -$91.3M LNTHLantheus Holdings, Inc.3.06x 28.11x $384M $27.8M
-
Which has Higher Returns IOVA or NTLA?
Intellia Therapeutics, Inc. has a net margin of -135.28% compared to Iovance Biotherapeutics, Inc.'s net margin of -735.19%. Iovance Biotherapeutics, Inc.'s return on equity of -54.43% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.
Company Gross Margin Earnings Per Share Invested Capital IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M NTLAIntellia Therapeutics, Inc.64.19% -$0.92 $846.4M -
What do Analysts Say About IOVA or NTLA?
Iovance Biotherapeutics, Inc. has a consensus price target of $8.35, signalling upside risk potential of 227.45%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $23.86 which suggests that it could grow by 81.42%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Intellia Therapeutics, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Intellia Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IOVAIovance Biotherapeutics, Inc.6 4 1 NTLAIntellia Therapeutics, Inc.9 11 1 -
Is IOVA or NTLA More Risky?
Iovance Biotherapeutics, Inc. has a beta of 0.765, which suggesting that the stock is 23.531% less volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.103, suggesting its more volatile than the S&P 500 by 110.271%.
-
Which is a Better Dividend Stock IOVA or NTLA?
Iovance Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iovance Biotherapeutics, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IOVA or NTLA?
Iovance Biotherapeutics, Inc. quarterly revenues are $67.5M, which are larger than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. Iovance Biotherapeutics, Inc.'s net income of -$91.3M is higher than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, Iovance Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iovance Biotherapeutics, Inc. is 3.38x versus 23.96x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IOVAIovance Biotherapeutics, Inc.3.38x -- $67.5M -$91.3M NTLAIntellia Therapeutics, Inc.23.96x -- $13.8M -$101.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Feb 2
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 1.22% over the past day.
Sell
34
PFSI alert for Feb 2
PennyMac Financial Services, Inc. [PFSI] is down 8.61% over the past day.
Sell
40
SHNY alert for Feb 2
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 9.87% over the past day.
